Insomnia Treatment Market to Reach US$ 5.1 Billion by 2031 at 4.3% CAGR, Driven by Rising Chronic Insomnia Prevalence (35% Share) and Growing Adoption of DORA Therapies with Key Players Sanofi S.A., Eli Lilly and Company, and Pfizer Inc.

The Insomnia Treatment Market reached US$ 3.7 billion in 2022 and is expected to reach US$ 5.1 billion by 2031 growing with a CAGR of 4.3% from 2024 to 2031. as healthcare providers and patients increasingly seek effective therapies to manage sleep disorders and improve overall quality of life.
Growth is supported by rising demand across key treatment segments such as pharmacological therapies (including benzodiazepine receptor agonists, non-benzodiazepine hypnotics, melatonin receptor agonists, and orexin receptor antagonists) and non-pharmacological interventions like cognitive behavioral therapy for insomnia (CBT-I), driven by the growing prevalence of sleep disturbances due to stress, lifestyle factors, and comorbid conditions. Advances in drug development, personalized treatment approaches, and digital therapeutics further accelerate market expansion by enhancing efficacy and patient adherence. Additionally, increased awareness of sleep health, improved diagnostic capabilities, and expanded access to care through telemedicine continue to propel broad adoption of insomnia treatment solutions worldwide.

Download your exclusive sample report today (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/insomnia-treatment-market?sindhuri

Insomnia Treatment Market: Competitive Intelligence
Sanofi S.A., Eli Lilly and Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Jazz Pharmaceuticals plc, H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Sunovion Pharmaceuticals Inc., and others.
The Insomnia Treatment Market is strongly driven by major global pharmaceutical and biotechnology companies such as Sanofi S.A., Eli Lilly and Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd., who develop, manufacture, and market a wide range of therapeutic treatments for insomnia including hypnotics, sedative-hypnotics (benzodiazepines and non-benzodiazepines), melatonin receptor agonists, orexin receptor antagonists, and combination drug therapies that help regulate sleep onset, improve sleep maintenance, and support overall sleep quality in patients suffering from sleep disorders.
Rising prevalence of insomnia and sleep disturbances driven by aging populations, lifestyle stress, comorbid conditions such as anxiety and depression, and increasing clinical awareness are key factors fueling market growth. Additionally, increased healthcare access, growing adoption of personalized treatment regimens, and expanding research into novel mechanisms of action (such as dual orexin receptor antagonism) are broadening therapeutic options and improving patient outcomes across geographies.
These companies' complementary strengths broad portfolio of branded and generic insomnia therapies from Sanofi, Pfizer, and Takeda; innovative clinical pipelines and research capabilities at Eli Lilly, Jazz Pharmaceuticals, and Novartis; established central nervous system focus from H. Lundbeck; diversified global distribution and market reach from Teva and Otsuka; and targeted product offerings from Sunovion enhance competitive positioning across the insomnia treatment landscape. Strategic focus areas include development of next-generation agents with improved efficacy and safety profiles, extended-release and patient-centric formulations, digital therapeutics integration, real-world evidence and outcomes-based studies, expansion into emerging markets, and strategic collaborations with healthcare providers and payers to increase treatment access and adherence.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/insomnia-treatment-market?sindhuri

Recent Key Developments - United States & North America
✅ June 2025: Eisai Co., Ltd. expanded commercialization efforts of its dual orexin receptor antagonist (DORA) therapy in the U.S., targeting adults with chronic insomnia and sleep maintenance difficulties.
✅ May 2025: Pfizer Inc. advanced clinical research programs focused on novel non-benzodiazepine insomnia treatments aimed at improving sleep onset with reduced dependency risks.
✅ 2025: Increasing stress levels, rising prevalence of mental health disorders, and growing awareness of sleep health significantly boosted demand for prescription and over-the-counter insomnia therapies across North America.

Recent Key Developments - Europe
✅ July 2025: Sanofi expanded its consumer healthcare portfolio in Europe with melatonin-based and herbal sleep aid formulations for mild to moderate insomnia.
✅ Early 2026: Idorsia Pharmaceuticals strengthened market presence of innovative insomnia drugs across major European countries, supported by regulatory approvals and reimbursement coverage.
✅ 2025: Increased adoption of cognitive behavioral therapy for insomnia (CBT-I) combined with pharmacological treatments contributed to a holistic approach to sleep disorder management in the region.

Recent Key Developments - Asia-Pacific
✅ June 2025: Takeda Pharmaceutical Company expanded insomnia treatment distribution across Japan and Southeast Asia, focusing on orexin receptor antagonist therapies.
✅ 2025: Cipla Limited increased availability of generic sleep medications and melatonin supplements in India and neighboring countries.
✅ 2025-2026: Urbanization, changing lifestyles, high smartphone usage, and growing work-related stress in China, India, Japan, and South Korea accelerated insomnia prevalence and treatment adoption.

Recent Key Developments - Product & Technology Innovation
✅ Dual Orexin Receptor Antagonists (DORAs): Growing adoption of next-generation therapies targeting wakefulness pathways with improved safety and reduced dependency risks.
✅ Digital Sleep Health Platforms: Integration of mobile apps, wearable sleep trackers, and telehealth consultations to support diagnosis and personalized treatment.
✅ Natural & Non-Habit Forming Solutions: Rising demand for melatonin, herbal supplements, and non-benzodiazepine drugs as safer long-term sleep management options.

✅ 1. M&A / Strategic Activity
Recent strategic moves shaping the insomnia treatment market:
Eli Lilly - Strategic expansion in sleep disorder portfolio
Eli Lilly expanded its sleep and CNS disorder pipeline through targeted collaborations and licensing agreements with biotech firms developing novel orexin receptor modulators and other sleep-promoting mechanisms to diversify beyond traditional hypnotic classes.
Merck - Acquisition of sleep technology assets
Merck strengthened its presence in the sleep health ecosystem by acquiring assets and partnerships related to digital therapeutic platforms that support insomnia assessment and behavioral intervention complementing pharmacologic treatment.
Pfizer - Partnerships for CNS and sleep science
Pfizer entered into partnership agreements with academic institutions and biotech innovators to co-develop insomnia therapies with novel targets, including combined approaches for sleep fragmentation and comorbid anxiety or depression.
Harmony Biosciences - Strategic licensing deals
Harmony Biosciences expanded licensing of its CNS asset platforms to include potential insomnia treatment extensions, aligning sleep applications with its broader neurological therapeutic focus.

✅ 2. New Product Launches & Regulatory Milestones
Recent product launches, approvals, and clinical development progress impacting insomnia therapy:
Merck - Belsomra (Suvorexant) label expansion
Merck's Belsomra (suvorexant) continues to receive expanded label updates in key markets, reinforcing its role as a dual orexin receptor antagonist (DORA) indicated for insomnia characterized by difficulties with sleep onset and/or maintenance.
Eisai - Dayvigo (Lemborexant) uptake acceleration
Eisai's Dayvigo (lemborexant), another DORA, saw increased adoption and supportive real-world evidence in adults with chronic insomnia, with expanded insurance coverage in select regions improving access.
Takeda/Idorsia - Daridorexant market growth
The orexin antagonist daridorexant continues to roll out in major markets, offering a new option in the DORA class with clinical data supporting improved sleep maintenance without next-day residual effects.
Digital Sleep Therapeutics - Companion apps and regulatory recognition
Several digital therapeutic platforms for insomnia (e.g., CBT-I apps) have gained increased recognition within clinical guidelines and payer frameworks as adjuncts to pharmacotherapy, expanding the treatment ecosystem.

✅ 3. R&D & Technological Advancements
Next-Generation Sleep Pharmacotherapies
Beyond DORAs, R&D is exploring GABA-A receptor modulators with improved safety profiles, melatonin receptor agonists with enhanced efficacy, and agents targeting circadian regulators to broaden mechanisms of action for insomnia.
Biomarker-Driven Personalization
Research is advancing toward biomarker and phenotype stratification (e.g., objective sleep onset latency, cortical EEG signatures) to tailor insomnia treatments to individual patients - reducing trial-and-error prescribing and improving outcomes.
Digital and Hybrid Therapeutic Models
Integration of digital Cognitive Behavioral Therapy for Insomnia (CBT-I) with pharmacologic regimens is a key trend, supported by AI-driven sleep trackers and real-time adherence feedback loops that enhance long-term sleep improvement.
Wearable & Sleep Monitoring Technologies
Advancements in wearable monitoring (EEG, actigraphy, and biosensors) are supporting objectively measured sleep metrics that inform clinical decision-making and objectively validate therapeutic responses.

Market Drivers & Emerging Trends
» Rising Prevalence of Insomnia - Increasing prevalence of sleep disorders globally, driven by stress, aging populations, and lifestyle factors, fuels demand for effective insomnia therapies.
» Shift Toward DORA Class Therapies - Dual orexin receptor antagonists offering symptom relief with favorable safety profiles are gaining momentum as preferred options over older hypnotics.
» Integration of Digital Therapeutics - Digital CBT-I and mobile monitoring tools complement pharmacotherapies and are being incorporated into treatment pathways.
» Focus on Personalized Medicine - Phenotype-specific treatment models and biomarker research are shaping next-generation insomnia approaches.
» Regulatory and Guidelines Support - Clinical guidelines are increasingly acknowledging the role of both pharmacologic agents and CBT-I digital tools in comprehensive insomnia management.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=insomnia-treatment-market?sindhuri

Segments Covered in the Insomnia Treatment Market:
By Type
The market is segmented into acute insomnia (30%), chronic insomnia (35%), onset insomnia (15%), maintenance insomnia (15%), and behavioral insomnia of childhood (5%).Chronic insomnia dominates due to its long-term nature and need for continuous therapeutic management. Acute insomnia accounts for a significant share, often triggered by stress, lifestyle changes, or medical conditions. Onset and maintenance insomnia represent specific sleep pattern disruptions requiring targeted pharmacological and behavioral interventions. Behavioral insomnia of childhood remains a niche but important segment driven by pediatric sleep disorder management.

By Drugs
The market includes zolpidem (30%), eszopiclone (20%), ramelteon (15%), zaleplon (15%), and estazolam (20%).Zolpidem leads due to its widespread prescription as a first-line sedative-hypnotic. Eszopiclone and estazolam are commonly used for chronic and severe insomnia cases. Ramelteon is gaining traction due to its melatonin receptor agonist mechanism and lower dependency risk. Zaleplon is preferred for short-term treatment of sleep-onset insomnia due to its rapid onset and short half-life.

By Distribution Channel
Distribution channels comprise hospital pharmacies (35%), retail pharmacies (45%), and online pharmacies (20%).Retail pharmacies dominate due to high outpatient prescription volumes and chronic therapy refills. Hospital pharmacies account for prescriptions initiated during inpatient care or specialist consultations. Online pharmacies are expanding rapidly with increasing telemedicine adoption and discreet home delivery services.

Regional Analysis
North America - 40% Share
North America leads due to high prevalence of sleep disorders, strong awareness of mental health, and high prescription rates in the U.S. and Canada.

Europe - 25% Share
Europe holds a substantial share driven by aging populations, increased stress-related disorders, and well-established pharmaceutical markets in Germany, the U.K., France, and Italy.

Asia-Pacific - 20% Share
Asia-Pacific is experiencing steady growth due to urbanization, rising work-related stress, increasing healthcare access, and growing awareness of sleep health in China, India, Japan, and South Korea.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sindhuri
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.